220 related articles for article (PubMed ID: 21851878)
1. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions.
Gurm HS; Dixon SR; Smith DE; Share D; Lalonde T; Greenbaum A; Moscucci M;
J Am Coll Cardiol; 2011 Aug; 58(9):907-14. PubMed ID: 21851878
[TBL] [Abstract][Full Text] [Related]
2. The association between contrast dose and renal complications post PCI across the continuum of procedural estimated risk.
Kooiman J; Seth M; Share D; Dixon S; Gurm HS
PLoS One; 2014; 9(3):e90233. PubMed ID: 24625555
[TBL] [Abstract][Full Text] [Related]
3. The changing definition of contrast-induced nephropathy and its clinical implications: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Slocum NK; Grossman PM; Moscucci M; Smith DE; Aronow HD; Dixon SR; Share D; Gurm HS
Am Heart J; 2012 May; 163(5):829-34. PubMed ID: 22607861
[TBL] [Abstract][Full Text] [Related]
4. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
Worasuwannarak S; Pornratanarangsi S
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
[TBL] [Abstract][Full Text] [Related]
5. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose.
Freeman RV; O'Donnell M; Share D; Meengs WL; Kline-Rogers E; Clark VL; DeFranco AC; Eagle KA; McGinnity JG; Patel K; Maxwell-Eward A; Bondie D; Moscucci M;
Am J Cardiol; 2002 Nov; 90(10):1068-73. PubMed ID: 12423705
[TBL] [Abstract][Full Text] [Related]
6. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
[TBL] [Abstract][Full Text] [Related]
7. Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention.
Chong E; Shen L; Poh KK; Tan HC
Singapore Med J; 2012 Mar; 53(3):164-9. PubMed ID: 22434288
[TBL] [Abstract][Full Text] [Related]
8. Contrast-induced nephropathy in patients undergoing endovascular peripheral vascular intervention: Incidence, risk factors, and outcomes as observed in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
Grossman PM; Ali SS; Aronow HD; Boros M; Nypaver TJ; Schreiber TL; Park YJ; Henke PK; Gurm HS
J Interv Cardiol; 2017 Jun; 30(3):274-280. PubMed ID: 28370487
[TBL] [Abstract][Full Text] [Related]
9. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
[TBL] [Abstract][Full Text] [Related]
10. Is renal function-based contrast dosing of radiographic contrast media in patients undergoing percutaneous coronary intervention sufficient to delineate safe limits of contrast dose?
Kalra N; Fenster P
J Am Coll Cardiol; 2012 Jan; 59(4):432; author reply 432-3. PubMed ID: 22261170
[No Abstract] [Full Text] [Related]
11. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
[TBL] [Abstract][Full Text] [Related]
12. Use of the contrast volume or grams of iodine-to-creatinine clearance ratio to predict mortality after percutaneous coronary intervention.
Tan N; Liu Y; Chen JY; Zhou YL; Li X; Li LW; Yu DQ; Chen ZJ; Liu XQ; Huang SJ
Am Heart J; 2013 Apr; 165(4):600-8. PubMed ID: 23537978
[TBL] [Abstract][Full Text] [Related]
13. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality.
Marenzi G; Assanelli E; Campodonico J; Lauri G; Marana I; De Metrio M; Moltrasio M; Grazi M; Rubino M; Veglia F; Fabbiocchi F; Bartorelli AL
Ann Intern Med; 2009 Feb; 150(3):170-7. PubMed ID: 19189906
[TBL] [Abstract][Full Text] [Related]
14. Impact of automated contrast injector systems on contrast use and contrast-associated complications in patients undergoing percutaneous coronary interventions.
Gurm HS; Smith D; Share D; Wohns D; Collins J; Madala M; Koneru S; Menees D; Chetcuti S
JACC Cardiovasc Interv; 2013 Apr; 6(4):399-405. PubMed ID: 23523450
[TBL] [Abstract][Full Text] [Related]
15. Contemporary use of and outcomes associated with ultra-low contrast volume in patients undergoing percutaneous coronary interventions.
Gurm HS; Seth M; Dixon SR; Michael Grossman P; Sukul D; Lalonde T; Cannon L; West D; Madder RD; Adam Lauver D
Catheter Cardiovasc Interv; 2019 Feb; 93(2):222-230. PubMed ID: 30144337
[TBL] [Abstract][Full Text] [Related]
16. The burgeoning epidemic of morbid obesity in patients undergoing percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
Buschur ME; Smith D; Share D; Campbell W; Mattichak S; Sharma M; Gurm HS
J Am Coll Cardiol; 2013 Aug; 62(8):685-91. PubMed ID: 23948512
[TBL] [Abstract][Full Text] [Related]
17. High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention.
Liu Y; Tan N; Zhou YL; Chen YY; Chen JY; Chen J; Luo JF
J Nephrol; 2012; 25(3):332-40. PubMed ID: 21928234
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty.
Ivanes F; Isorni MA; Halimi JM; Fauchier L; Saint Etienne C; Babuty D; Angoulvant D; Brunet-Bernard A
Arch Cardiovasc Dis; 2014; 107(8-9):424-32. PubMed ID: 25082735
[TBL] [Abstract][Full Text] [Related]
19. Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.
Barbieri L; Verdoia M; Schaffer A; Cassetti E; Marino P; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2015 Feb; 25(2):181-6. PubMed ID: 25315668
[TBL] [Abstract][Full Text] [Related]
20. Contemporary use and effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy among patients undergoing percutaneous coronary intervention.
Gurm HS; Smith DE; Berwanger O; Share D; Schreiber T; Moscucci M; Nallamothu BK;
JACC Cardiovasc Interv; 2012 Jan; 5(1):98-104. PubMed ID: 22230155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
